Cytokinetics to Participate in Upcoming Investor Conferences
Cytokinetics, Incorporated (Nasdaq: CYTK) announced that CEO Robert I. Blum will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 11:45 am ET in Miami Beach. Interested parties can access live and archived webcasts of both events on Cytokinetics' website for 90 days post-event. The company is focused on developing muscle activators and inhibitors, with significant products in the pipeline, including omecamtiv mecarbil and aficamten.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 11:45 am ET at the Loews Miami Beach Hotel in Miami Beach.
Interested parties may access the on-demand and live webcasts of the presentation and fireside chat by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The replay of each presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Joanna Siegall
Associate Director, Corporate Communications, Investor Relations
(425) 314-1721
FAQ
When is Cytokinetics presenting at the Oppenheimer Healthcare Conference?
Where can I watch the Cytokinetics presentations?
What is the focus of Cytokinetics' research and development?
What are the significant products in Cytokinetics' pipeline?
When can I access the replay of the Cytokinetics presentations?
